For more information about these press releases, or about RFS Pharma in general,
please contact us.
February 6, 2012
RFS Pharma and Genoscience enter worldwide license agreement with BioLineRx to develop and commercialize hepatitis C virus (HCV) protease inhibitor.
Full Text
SOURCE: RFS Pharma, LLC
December 13, 2010
RFS Pharma's new dioxolane prodrugs have potent and selective anti-HIV activity.
Full Text
SOURCE: RFS Pharma, LLC
November 15, 2010
RFS Pharma Awarded Therapeutic Tax Credit and Announces the Approval by the U.S. FDA to Initiate a Phase 2 Study on the Anti-HIV Drug Amdoxovir�.
Full Text
SOURCE: RFS Pharma, LLC
November 8, 2010
RFS Pharma Awarded NIH Supplement Grant to Continue the Development of Novel Anti-HIV Drugs.
Full Text
SOURCE: RFS Pharma, LLC
October 4, 2010
RFS Pharma to Present at Upcoming Southeastern BIO Investor Forum.
Full Text
SOURCE: RFS Pharma, LLC
August 13, 2008
RFS Pharma and WACKER Announce Assignment Agreement for an Improved Synthetic Process to Manufacture Amdoxovir�.
Full Text
SOURCE: RFS Pharma, LLC
February 6, 2008
RFS
Pharma Announces a 2 log Plasma Viral Load Decline Following 10 Day
Treatment with a Dual Combination of Amdoxovir� (DAPD) and Retrovir�
(AZT) in HIV-1 Infected Individuals.
Full Text
SOURCE: RFS Pharma, LLC
June 19, 2007
RFS Pharma, LLC and Genoscience Pharma Sign Joint Venture Agreement to Discover and Develop Protease Inhibitors.
Full Text
SOURCE: RFS Pharma, LLC
May 29, 2007
RFS Pharma, LLC Awarded NIH Grant to Develop Resistance Repellent Anti-HIV Drugs.
Full Text
SOURCE: RFS Pharma, LLC
October 4, 2006
RFS Pharma, LLC Announces ACLIRES International Ltd. to Conduct Phase 2 HIV Study.
Full Text
SOURCE: RFS Pharma, LLC
May 7, 2006
RFS Pharma Announces Appointment of Dr. Steven J. Coats as Senior Director of Chemistry.
Full Text
SOURCE: RFS Pharma, LLC
February 13, 2006
RFS
Pharma Announces 2-Week Data from an NIH-Sponsored Phase 2 Clinical
Trial Evaluating Amdoxovir� (AMDX) in Highly Treatment-Experienced
HIV-1 Infected Individuals.
Full Text
SOURCE: RFS Pharma, LLC
